Business Context and Reporting Period
Company: Redhill Biopharma Ltd. (Nasdaq: RDHL)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: June 8, 2026
Business Overview: A specialty biopharmaceutical company focused on gastrointestinal diseases, infectious diseases, and oncology. Key assets include the FDA-approved drug Talicia (co-commercialized with Cumberland Pharmaceuticals) and late-stage clinical programs such as opaganib, RHB-102 (Bekinda), RHB-204, and RHB-107.
Key Financial Metrics
This filing is a current report regarding a legal enforcement action and does not contain a financial statement or quarterly results. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
- Legal Judgment Value: Approximately $10.9 million total awarded by the New York Supreme Court against Kukbo Co. Ltd.
- Breakdown of Award: ~$8.9 million principal judgment and ~$1.95 million in legal fees and expenses.
- Interest: 9% statutory interest accrues on the awarded amounts.
Material Changes and Legal Developments
The primary material event reported is the commencement of enforcement proceedings in Korea regarding a final New York Supreme Court judgment against Kukbo Co. Ltd.
- Finality of Judgment: The principal award became final in November 2025. The award for legal fees became final in March 2026 after Kukbo failed to perfect an appeal. No further appeals are permissible.
- Enforcement Action: RedHill has served Kukbo in Korea to recognize and enforce the $10.9 million judgment.
- Asset Protection: RedHill previously secured a Korean court attachment grant to prevent Kukbo from disposing of assets prior to enforcement.
- Current Status: The Company is awaiting Kukbo's response and further scheduling by the Korean court.
Outlook, Risks, and Management Commentary
Management has initiated enforcement but explicitly stated that no assurances can be provided regarding the timing of recovery or the amount that may be recovered, including whether the Company will recover all or any portion of the awarded amounts.
Key Risks Disclosed:
- Enforcement Risk: Potential failure to succeed in the Korean enforcement action or inability to collect the full judgment amount.
- Listing Compliance: Risk regarding the ability to regain and maintain compliance with Nasdaq listing requirements, specifically the minimum bid price requirement.
- Development Risks: Uncertainty regarding the efficacy and regulatory approval of pipeline candidates (opaganib, RHB-102, RHB-204, RHB-107) and potential cessation of U.S. government R&D funding.
- Commercialization: Risks associated with the commercial success of Talicia and the ability to secure future milestone payments.
Investor Verification Checklist
- Verify the current status of the Korean court proceedings and any response filed by Kukbo Co. Ltd.
- Confirm RedHill's current cash position and runway, as this filing does not provide updated liquidity data.
- Review the Company's most recent Form 20-F (filed April 27, 2026) for detailed financial statements and Nasdaq compliance status.
- Monitor updates on the clinical progress of opaganib and RHB-102, as these are critical to future revenue generation.
- Assess the likelihood of asset recovery from Kukbo given the jurisdictional complexities of enforcing a U.S. judgment in Korea.